A behind-the-scenes look at some of the challenges being faced by executives trying to develop drugs in today’s current R&D environment. The Price Of Market Access - Part 3 of 4.

Imagine you get that call from a Big Pharma. They tell you they are divesting X, which is not part of a strategic reprioritization. In other words, they’re not exiting that therapeutic category, just this particular target/product. How do you know what to look for in determining if it is a quality asset or if it actually belongs in the garbage dump?

Hurdles, Pricing And Patents: Part 2 of 4

As Jennifer Cook strides across the stage at the Hilton New York Midtown, it is difficult to envision the 2016 Healthcare Businesswomen’s Association’s (HBA) Woman of the Year (WOTY) as being anything but extremely confident. But during her acceptance speech, the Roche executive paints a very different portrait of her early self. “When I was growing up, I was shy, very studious, and quite frankly, insecure,” she admits. “I’ve always had a strong regard for authority and was very willing to follow instructions, trusting that people in charge must know best.”

A behind-the-scenes look at the challenges faced by drug companies trying to develop what are often pricy treatments to meet our unmet medical demands. Part 1 of 4: What Can Be Learned From Gilead’s Sovaldi?

Though the biopharmaceutical industry closed out the second quarter of 2015 with a 32 percent increase in VC investment when compared to the quarter previous, the second half of the year seemed to indicate that the biotech bubble might soon pop.

On Thursday, May 12, the Healthcare Businesswomen’s Association (HBA) will host its 27th annual Woman of the Year (WOTY) at the Hilton New York Midtown. The celebration draws over 2,000 women and men from throughout the healthcare industry and showcases the HBA’s core purpose of furthering the advancement and impact of women in the business of healthcare.

Having had the opportunity to attend an invitation-only event focused on biopharmaceutical R&D, what follows is a behind the scenes glimpse of what VCs look for when engaging with biopharmaceutical company heads of R&D as they weed, seed, and water those assets within their portfolios.

Having begun my preparations for the upcoming BIO 2016 International Convention, June 6 – 9 at the Moscone Center in San Francisco, I thought I would share some insights to help with your planning. First, in case you weren’t aware, the Moscone Center consists of three separate buildings: Moscone Center West, North, and South (see map here). While this might not seem like a big deal, if you plan on attending some of the educational sessions, a little preplanning could prevent you from missing something important (e.g., the Monday June 6, Welcome Reception at the Exploratorium at Pier 15).